{
    "nct_id": "NCT03915496",
    "official_title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO INVESTIGATE THE MECHANISM OF ACTION OF ABROCITINIB MONOTHERAPY IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS",
    "inclusion_criteria": "* Clinical diagnosis of chronic moderate-to-severe atopic dermatitis (AD) for at least 1 year\n* Recent history of inadequate response to medicated topical therapy for AD or required systemic therapy to control disease\n* Moderate-to-severe AD defined as affected BSA at least 10%, IGA at least 3, EASI at least 16, Peak Pruritus NRS at least 4\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* A current or past medical history of conditions associated with thrombocytopenia, coagulopathy, or platelet dysfunction\n* Currently have active forms of other inflammatory skin diseases, i.e. not AD, or have evidence of skin conditions (e.g. psoriasis, seborrheic dermatitis, lupus) at the time of Day 1 that would interfere with evaluation of AD or response to treatment\n* Participants who have received prior treatment with any systemic JAK inhibitors\n* Require treatment with prohibited concomitant medication(s) or have received a prohibited concomitant medication within specified time frames prior to the first dose of study medication, including topical treatments that could affect AD\n* Pregnant or breastfeeding women or sexually-active women of childbearing potential who are unwilling to use contraception",
    "miscellaneous_criteria": ""
}